Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
completion around

Description

Summary

The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.

Official Title

A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy

Keywords

Chronic Inflammatory Demyelinating Polyneuropathy, Polyneuropathies, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, riliprubart, IVIg

Eligibility

Locations

  • University of California Irvine Medical Center- Site Number : 8400007 accepting new patients
    Orange California 92868 United States
  • Keck School of Medicine of University of Southern California- Site Number : 8400002 accepting new patients
    Los Angeles California 90033 United States
  • ~Mass General Hospital- Site Number : 8400009 accepting new patients
    Boston Massachusetts 92114 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Sanofi
ID
NCT06290141
Phase
Phase 3 Neuropathy Research Study
Study Type
Interventional
Participants
Expecting 160 study participants
Last Updated